The European Medicines Agency would like
to inform you that the new PRIME (PRIority MEdicines) scheme to
strengthen support to medicines that target an unmet medical need has
been launched today. The scheme focuses on medicines that may offer a
major therapeutic advantage over existing treatments, or benefit
patients with no treatment options. Through PRIME, the Agency offers
early, proactive and enhanced support to medicine developers to optimise
the generation of robust data on a medicine’s benefits and risks and
enable accelerated assessment of marketing applications.
A press release
on PRIME and further information have been published on the EMA
website, including details on how to apply. In the event of queries, a
dedicated e-mail has been set up (
prime@ema.europa.eu).
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου